View Older Stories View More Recent Stories

Oct 3, 2022 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 3, 2022 05:52AM Cytokinetics (CYTK) Presents New Data From REDWOOD-HCM OLE
Oct 2, 2022 09:45AM Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Sep 30, 2022 10:30AM Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions
Sep 28, 2022 07:30AM Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
Sep 26, 2022 07:30AM Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting
Sep 6, 2022 04:00PM Cytokinetics to Participate in Upcoming Investor Conferences
Sep 1, 2022 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2022 04:00PM Cytokinetics Reports Second Quarter 2022 Financial Results
Aug 4, 2022 07:30AM Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials
Aug 1, 2022 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 21, 2022 04:00PM Cytokinetics to Announce Second Quarter Results on August 4, 2022
Jul 5, 2022 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jun 24, 2022 07:31AM Cytokinetics (CYTK) Announces December 13, 2022 as AdCom Date for Omecamtiv Mecarbil, PDUFA of February 28, 2023
Jun 24, 2022 07:30AM Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
Jun 17, 2022 07:31AM Cytokinetics (CYTK) Provides Additional omecamtiv mecarbil Information to FDA, Announces 3 Month PDUFA Extension
Jun 17, 2022 07:30AM Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil
Jun 16, 2022 07:30AM Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS
Jun 13, 2022 07:30AM Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
Jun 3, 2022 04:01PM Cytokinetics (CYTK) Posts Additional Results From REDWOOD-HCM
Jun 3, 2022 04:00PM Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
Jun 2, 2022 04:00PM Cytokinetics to Participate in Upcoming Investor Conferences
Jun 1, 2022 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 23, 2022 11:30AM Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
May 18, 2022 07:30AM Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
May 17, 2022 04:00PM Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
May 17, 2022 07:32AM Cytokinetics (CYTK) Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
May 17, 2022 07:30AM Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
May 16, 2022 04:00PM Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
May 4, 2022 04:00PM Cytokinetics Reports First Quarter 2022 Financial Results
May 3, 2022 04:00PM Cytokinetics to Hold Annual Meeting of Stockholders
May 2, 2022 04:01PM Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
Apr 20, 2022 04:00PM Cytokinetics to Announce First Quarter Results on May 4, 2022
Apr 8, 2022 07:32AM Cytokinetics (CYTK) Announces Changes to Board of Directors
Apr 8, 2022 07:30AM Cytokinetics Announces Changes to Board of Directors
Apr 6, 2022 04:00PM Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
Apr 3, 2022 09:45AM Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
Apr 2, 2022 11:30AM Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session
Apr 1, 2022 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 24, 2022 04:00PM Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo
Mar 8, 2022 04:00PM Cytokinetics to Participate in Upcoming Investor Conferences
Mar 2, 2022 07:30AM Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment
Mar 1, 2022 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Feb 28, 2022 07:30AM Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
Feb 24, 2022 04:00PM Cytokinetics Reports Fourth Quarter 2021 Financial Results
Feb 23, 2022 07:33AM Cytokinetics (CYTK) Commences SEQUOIA-HCM Phase 3 Clinical Trial of Aficamten
Feb 23, 2022 07:30AM Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Feb 16, 2022 07:30AM Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease
Feb 15, 2022 07:32AM Cytokinetics (CYTK) Reports METEORIC-HF Trial Failed to Meet Endpoints
Feb 15, 2022 07:30AM Cytokinetics Announces Topline Results From METEORIC-HF
View More Recent Stories View Older Stories